Research and Development.
Partnerships and services to drive innovation.
At inbiome research and development is at the heart of everything we do. With our team of microbiologists, biomedical scientists, bioinfomaticians and AI specialists we work on various cutting edge research projects. Closely partnering with universities and hospitals to explore promising new fields of bacterial diagnostics and microbiome related preventive and predictive healthcare.
Let’s shape the future together.
We are always open to discuss promising new research topics and see where we can help, either as a service provider or as a research partner. Additional to our R&D capabilities, our experience with guiding new applications from the R&D stage through clinical validations and regulatory approvals to commercial use in hospitals can add value in new product development trajectories.
Capabilities.
We offer microbiome analysis solutions and reporting services for better insights of microbial populations and their functions. Inbiome can help you analyse the human microbiome to measure differences between treatments and determine how a product interacts with the microbiome. We can support you in all requirements needed to demonstrate a product in the context of the microbiome. Make use of our experience and service packages to gain more insight into your research questions.
Cases.
Inflammatory Bowel Disease (IBD)
Molecular Culture® Microbiota has been used extensively in researching on Inflammatory Bowel Disease. Large cohorts of children and adults in different phases of their disease (exacerbation/remission) have been performed. Moreover, as an outcome of the MODAPEP project, inbiome developed a test for research purposes that is paving the way for doctors to identify patients susceptible to an exacerbation in time to treat the disease before the symptoms flare up.
Conclusion
with Molecular Culture, the diagnosis was made faster than traditional culture and the patient could have been cured much sooner.
Fecal Microbiota Transpant (FMT)
Inbiome performed a study on the impact of FMT in Irritable Bowel Syndrome (IBS) patients by using Molecular Culture® Microbiota. Results showed that the therapy effect on symptoms varies and depends on the specific donor. Moreover, by monitoring the composition of patients’ gut microbiota, inbiome was able to assess the engraftment of the transplant feces and link it to effects on wellbeing.
Conclusion
with Molecular Culture, the diagnosis was made faster than traditional culture and the patient could have been cured much sooner.
Skin experiments
To understand what are the effects of cosmetic products such as soap and deodorants on the microbiota, inbiome performed microbial analysis on the skin using Molecular Culture® Microbiota. Results showed that the microbiota composition of different body sites changed over time, but overall remained healthy, meaning that cosmetic products do not have a detrimental effect on skin microbiota.
Conclusion
with Molecular Culture, the diagnosis was made faster than traditional culture and the patient could have been cured much sooner.